Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer
- 26 February 2007
- journal article
- Published by Wiley in Colorectal Disease
- Vol. 9 (9) , 793-800
Abstract
Objective Microvessel density (MVD) has been studied as a prognostic marker in human cancers. Quantification of lymphatic vessel density (LVD) is now possible by using new antibodies. Expression of the lymphangiogenic growth factors, VEGF‐C and VEGF‐D, is associated with poorer clinicopathological outcomes in various tumours. The aim of this study was to quantify LVD and MVD in colorectal cancer, determine the relationship between LVD, MVD and clinicopathological variables and examine the relationship between LVD and tumour expression of VEGF‐C and VEGF‐D.Method Thirty primary colorectal cancers were immunostained for CD34, lymph vessel endothelial hyaluronan receptor‐1 (LYVE‐1), VEGF‐A and VEGF‐D using standard techniques. LVD and MVD were determined by Chalkley grid counting. Tumours were assessed for the presence or absence of LYVE‐1 positive lymphatics at different areas within the tumour and the tumour was scored for VEGF‐C and VEGF‐D immunostaining intensity at the invading tumour edge. Non‐parametric tests were used for statistical analysis and a P‐value of Results Lymph vessel endothelial hyaluronan receptor‐1 was an excellent lymphatic vessel marker. Within normal bowel wall, lymphatic vessels were found rarely in the superficial colonic mucosa, but were numerous in the submucosa and muscularis propria. In the majority of tumours, lymphatic vessels were located in the peri‐tumoural area, intra‐tumoural vessels were sparse and tended to be narrow with closed lumina. At the invading tumour edge, VEGF‐C expression was higher (P = 0.028) and VEGF‐D expression lower (P = 0.011), in tumours in which lymphatic vessels were present. No significant differences between LVD and any clinicopathological variable or route of metastasis were identified.Conclusion Lymphatic vessel density and MVD can be quantified in colorectal carcinoma using immunohistochemical techniques. The balance between expression of VEGF‐C and VEGF‐D at the invading tumour edge may enhance lymphatic metastasis, by promoting tumour lymphangiogenesis or by activation of pre‐existing lymphatic vessels. No relationship was identified between LVD and clinicopathological variables.Keywords
This publication has 36 references indexed in Scilit:
- The angiogenic switch for vascular endothelial growth factor (VEGF)‐A, VEGF‐B, VEGF‐C, and VEGF‐D in the adenoma–carcinoma sequence during colorectal cancer progressionThe Journal of Pathology, 2003
- Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancerThe Journal of Pathology, 2003
- Lymphatic Metastasis in the Absence of Functional Intratumor LymphaticsScience, 2002
- Intratumoral Lymphatic Vessels: A Case of Mistaken Identity or Malfunction?JNCI: Journal of the National Cancer Institute, 2002
- Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluationEuropean Journal of Cancer, 1996
- Tumor Angiogenesis as a Predictor of Recurrence and Survival in Patients with Node-Negative Colon CancerAnnals of Surgery, 1995
- Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysisThe Journal of Pathology, 1995
- Tumor angiogenesis and rectal carcinomaDiseases of the Colon & Rectum, 1994
- Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast CarcinomaNew England Journal of Medicine, 1991
- Structure and Function of Lymphatics.Journal of Investigative Dermatology, 1989